Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy.
Marshall
John
J
Genzyme Corporation, Framingham, MA 01701-9322, USA. John.marshall@genzyme.com
McEachern
Kerry Anne
KA
Chuang
Wei-Lien
WL
Hutto
Elizabeth
E
Siegel
Craig S
CS
Shayman
James A
JA
Grabowski
Greg A
GA
Scheule
Ronald K
RK
Copeland
Diane P
DP
Cheng
Seng H
SH